Ghost Tree Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Ghost Tree Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-225,000	Closed	-$578K	–	75
2024 Q2	$578K	Sell	225,000 -225,000	-50%	-$768K	0.18%	60
2024 Q1	$2.21M	Buy	450,000 +75,000	+20%	+$444K	0.61%	54
2023 Q4	$3.3M	Buy	375,000 +25,000	+7%	+$205K	1.08%	32
2023 Q3	$4.01M	Sell	350,000 -175,000	-33%	-$3.36M	1.32%	29
2023 Q2	$13.3M	Buy	525,000 +275,000	+110%	+$8.57M	4.39%	7
2023 Q1	$8.05M	Sell	250,000 -50,000	-17%	-$1.56M	2.38%	15
2022 Q4	$5.54M	Sell	300,000 -90,000	-23%	-$2.06M	2.36%	18
2022 Q3	$10.5M	Buy	+390,000	New	+$7.91M	2.96%	14
2017 Q3	–	Sell	-89,295	Closed	-$2.36M	–	76
2017 Q2	$2.36M	Buy	+89,295	New	+$1.99M	0.49%	59
2015 Q2	–	Sell	-200,000	Closed	-$4.15M	–	85
2015 Q1	$4.15M	Buy	+200,000	New	+$3.46M	1.49%	27
2014 Q3	–	Sell	-20,000	Closed	-$680K	–	84
2014 Q2	$680K	Hold	20,000	–	–	0.48%	49
2014 Q1	$630K	Buy	+20,000	New	+$625K	0.37%	56

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Ghost Tree Capital's RVNC Position: Q3 2024 in Review

Ghost Tree Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 225,000 shares — an estimated $578K sold.

Ghost Tree Capital first reported a position in RVNC in Q1 2014 and held it in 12 quarters. The position peaked at $13.3M in Q2 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

Ghost Tree Capital reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
Ghost Tree Capital sold 225,000 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $578K.
Ghost Tree Capital first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 12 quarters.
Ghost Tree Capital's Revance Therapeutics, Inc. position peaked at $13.3M in Q2 2023.
201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.